Innovative Medicines Initiative (IMI) has recently published an update on the #ARDAT project: viruses can be hijacked to help cure rare diseases, but the immune system keeps fighting back. The team behind the ARDAT project is trying to answer some of the most perplexing questions surrounding viral gene and cell therapy, in the hope of getting us closer to new treatments for rare diseases. ARDAT wants to know more about the behaviour of gene and cell therapy treatments, delivered by viral vectors, once they’re inside the body.
As a reminder, the ARDAT Consortium, led by Pfizer and the The University of Sheffield and supported by Europe’s Innovative Medicines Initiative (IMI), aims to help standardize and accelerate the development of Advanced Therapy Medicinal Products (#ATMPs), providing tools to advance the knowledge in the field of viral gene/cell therapy to accelerate the development of new treatments for rare diseases and allowing potentially transformative treatments to reach patients sooner.
This 5-year European consortium brings together the leading expertise of 34 academic, non-profit and private organizations including ASPHALION, which will provide continuous #regulatorysupport to all partners during the life of the project and co-lead the regulatory work package 5 (engagement with regulators and database development).
ASPHALION is proud and excited to participate in the consortium and looks forward to a challenging and fruitful collaboration with all partners. For more information on ARDAT, please visit: www.ardat.org #horizon2020
Read here the complete ARDAT project update new.